University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
Health and Biomedical Sciences Faculty
Publications and Presentations

College of Health Professions

2012

Biocompatible Gold Nanorod Conjugates for Preclinical
Biomedical Research
Anton Liopo
André Conjusteau
Dmitri Tsyboulski
Boris Ermolinsky
The University of Texas Rio Grande Valley

Alexander V. Kazanksy
The University of Texas Rio Grande Valley

See next page for additional authors

Follow this and additional works at: https://scholarworks.utrgv.edu/hbs_fac
Part of the Medicine and Health Sciences Commons

Recommended Citation
Liopo, A., Conjusteau, A., Tsyboulski, D., Ermolinsky, B., Kazansky, A., & Oraevsky, A. (2012). Biocompatible
Gold Nanorod Conjugates for Preclinical Biomedical Research. Journal of nanomedicine &
nanotechnology, S2, 001. https://doi.org/10.4172/2157-7439.S2-001

This Article is brought to you for free and open access by the College of Health Professions at ScholarWorks @
UTRGV. It has been accepted for inclusion in Health and Biomedical Sciences Faculty Publications and
Presentations by an authorized administrator of ScholarWorks @ UTRGV. For more information, please contact
justin.white@utrgv.edu, william.flores01@utrgv.edu.

Authors
Anton Liopo, André Conjusteau, Dmitri Tsyboulski, Boris Ermolinsky, Alexander V. Kazanksy, and
Alexander Oraevsky

This article is available at ScholarWorks @ UTRGV: https://scholarworks.utrgv.edu/hbs_fac/54

Nanomedicine & Nanotechnology

Liopo et al. J Nanomedic Nanotechnol 2012, S2
http://dx.doi.org/10.4172/2157-7439.S2-001

Research Article

Open Access

Biocompatible Gold Nanorod Conjugates for Preclinical Biomedical
Research
Anton Liopo1*, André Conjusteau1, Dmitri Tsyboulski1, Boris Ermolinsky2, Alexander Kazansky2 and Alexander Oraevsky1
1
2

TomoWave Laboratories, Houston, TX 77081, USA
Department of Biomedicine, University of Texas at Brownsville, TX 78520, USA

Abstract
Gold nanorods with a peak absorption wavelength of 760 nm were prepared using a seed-mediated method. A
novel protocol has been developed to replace hexadecyltrimethylammonium bromide on the surface of the nanorods
with 16-mercaptohexadecanoic acid and metoxy-poly(ethylene glycol)-thiol, and the monoclonal antibody HER2. The
physical chemistry properties of the conjugates were monitored through optical and zeta-potential measurements to
confirm surface chemistry changes. The efficiency of the modifications was quantified through measurement of the
average number of antibodies per gold nanorod. The conjugates were investigated for different cells lines: BT-474, MCF7,
MCF10, MDCK, and fibroblast. The results show successful cell accumulation of the gold nanorod HER2 conjugates
in cells with HER2 overexpression. Incubation of the complexes in heparinized mouse blood demonstrated the low
aggregation of the metallic particles through stability of the spectral properties, as verified by UV/VIS spectrometry.
Cytotoxicity analysis with LDH release and MTT assay confirms strong targeting and retention of functional activity of
the antibody after their conjugation with gold nanorods. Silver staining confirms efficient specific binding to BT-474 cells
even in cases where the nanorod complexes were incubated in heparinized mouse blood. This is confirmed through in
vivo studies where, following intravenous injection of gold nanorod complexes, silver staining reveals noticeably higher
rates of specific binding in mouse tumors than in healthy liver.
The conjugates are reproducible, have strong molecular targeting capabilities, have long term stability in vivo and
can be used in pre-clinical applications. The conjugates can also be used for molecular and optoacoustic imaging,
quantitative sensing of biological substrates, and photothermal therapy.

Keywords: Gold nanorod fabrication; Metallic nanoparticles;
Biocompatible targeting agent; Gold surface modification; Antibody
conjugation; Cell particle targeting

Introduction
Gold nanoparticles of various shapes have promising applications
for the biomedical field [1-5]. Gold nanoparticles (NPs) have become
a focus of interest in the fields of nanobiotechnology and biomedicine
because of the ease of surface bioconjugation with molecular probes as
well as remarkable optical properties related to the Localized Surface
Plasmon Resonance (LSPR) [2,6-8]. LSPR of gold nanoparticles
results in strong optical absorption and scattering at visible and nearinfrared wavelengths [6,9]. One type of gold nanoparticle with a strong
tunable plasmon resonance in the near-infrared spectral range is the
gold nanorod (GNR) [6]. GNR can absorb light about one thousand
times more strongly than an equivalent volume of an organic dye
[6,10]. Consequently, GNR have been employed in diagnostics [11],
therapeutic-delivery systems [12], including small-molecule drugs
[13] and exogeneous nucleic acids [14], imaging [15,16], sensing
[17], and responsive advanced material assemblies [18]. Properties
such as biocompatibility ease of functionalization, and near infrared
optical imaging make gold nanorods promising in new theranostic
platforms [4]. GNRs were also used as optoacoustic (OA) contrast
agents for quantitative flow analysis in biological tissues [19] and to
investigate the kinetics of drug delivery compounds [20] or contrasting
imaging [16]. GNR stabilized with cetyltrimethylammonium bromide
(CTAB) shows cytotoxicity [21]. To reduce CTAB cytotoxicity, gold
nanoparticles in the solution are washed by centrifugation [22].
However, GNR require pegylation for in vivo, and many other types of
applications where the CTAB layer is being replaced by poly(ethylene
glycol). [21,22]. The modification of GNR is usually performed by
adding poly(ethylene glycol) thiol (r-PEG-SH, or simply PEG) to the
CTAB coated GNR solution, followed by the removal of the excess
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CTAB via dialysis or centrifugation [4,20,21,23,24]. The reasons
for PEGylation of nanoparticle surface, i.e. the covalent attachment
through thiol terminated PEG [25], includes shielding of antigenic
and immunogenic epitopes, shielding receptor-mediated uptake by
the Reticuloendothelial System (RES), and preventing recognition and
degradation by proteolytic enzymes [26]. PEG-modified GNR showed
a negative surface potential [22], as well as low level cytotoxicity in vitro
[21], and can therefore be used for biomedical applications [27].
After intravenous administration, GNRs get distributed inside the
body according to their modified affinity resulting in the enhancement
of the targeted tissues [28]. The use of structurally modified GNR is
less toxic to normal tissue during delivery. At the molecular level,
GNR could traverse biologic barriers and preferentially accumulate
in cancer cells [9, 29-31]. Targeting GNR to a specific site is a critical
aspect of bioimaging when used as a contrast agent. It is also critical for
achieving efficient photothermal therapy without side effects, especially
after intravenous injection [32].
Methods for enhancing the accumulation in cells and tissues
with strongly absorbing gold nanoparticles and gold nanorods were
previously discussed [2,4,5]. The standard for conjugating antibodies
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to gold nanoparticles using covalent bonding was published by several
research groups [1,4,33-35].
However, the conjugation processes are in need of improvement.
Most protocols are hard to adapt to large-scale manufacturing of highly
concentrated conjugates with strong affinity toward factors such as
biochemical and physiological conditions of the cells and organs of the
body [35].
In these studies, we adopted the published methodology of GNR
fabrication [34,36,37] to get a high yield of narrow band GNR with
optical absorption centered at 760 nm. The manufactured nanorods
were pegylated and conjugated with monoclonal antibody (mAb)
to become non-toxic as biocompatible agent. We characterized the
conjugation efficiency of the monoclonal antibody (mAb) HER2/neu
by measuring and comparing antibody binding of the GNRs before
and after pegylation. We devised a novel protocol through reordering
the steps involved in PEGylating GNR mAB conjugates for use in
preclinical research with specific accumulation in tumors.

Materials and Methods
Reagents
The chemicals used in this study were purchased from the following
companies: Hexadecyltrimethylammonium bromide (CTAB, Sigma),
Gold(III) chloride trihydrate (HAuCl4·3H2O, Aldrich), Sodium
Borohydride (NaBH4, Aldrich), Silver Nitrate (AgNO3, Sigma-Aldrich),
Ascorbic Acid (Sigma), Potassium carbonate (K2CO3, Sigma- Aldrich),
Poly (ethylene glycol) methyl ether thiol or Methoxypolyethylene glycol
thiol mPEG thiol, MW 5000, (mPEG-Thiol or PEG, Laysan Bio Inc.),
16-Mercaptohexadecanoic acid (MHDA, Sigma), Sodium Chloride
(NaCl, Sigma), 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide
hydrochloride (EDC, Pierce), N-hydroxysulfosuccinimide (sulfoNHS, Pierce), 2-(N-Morpholino) ethane sulfonic acid sodium salt
buffer (MES, Sigma-Aldrich), Monoclonal antibody Herceptin (HER2,
Genentech), trypan blue (Sigma), Phosphate buffered saline (PBS,
Sigma), tris-buffered saline with Tween-20 (TBST, Dako, Denmark),
target retrieval solution (TRS, Dako, Denmark).
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GNR,

			

Protocol 1
The GNR-CTAB complex was resuspended in 1 ml of MQW. The
GNR solution was then added to solutions of MHDA and PEG in molar
ratio of 1 to 4 (or 2 mM and 8 mM respectively). This molar ratio was
found experimentally: the optimal ratio was chosen as maximizing the
area covered by the linker MHDA, therefore increasing the likelihood
1.20

1.00

and

We present below the details of a GNR fabrication protocol adapted
from previously reported methodology [34,37, 38]. The base procedure
is tailored to the needs of the specific experiments presented in this
paper. It allows high-yield fabrication of a narrow size distribution of
rods with a 760 nm plasmon resonance. In a typical procedure, 0.250
ml of an aqueous 0.01 M solution of HAuCl4·3H2O was added to 7.5 ml
of a 0.1 M CTAB solution in a test tube (15 ml glass tube). Then, 0.600
ml of an aqueous 0.01 M ice-cold NaBH4 solution was added all at once.
This seed solution was used 2-3 hours after its preparation. In the next
step of the fabrication, exact proportions of 9.5 mL of 0.10 M CTAB,
0.400 ml of 0.01 M HAuCl4·3H2O, and 0.060 ml of 0.01 M AgNO3
solutions were added one at a time in the preceding order, then gently
mixed by inversion. The solution at this stage appeared bright brownyellow in color. Then 0.064 ml of 0.10 M ascorbic acid was added. The
solution became colorless upon addition and mixing of ascorbic acid.
Ten minutes were allowed for the reaction to fully proceed before
adding the required quantity of seed solution. The reaction mixture was
gently mixed for 10 seconds and left undisturbed for 1-2 hours. Then,
the solution was left under thermostatic conditions for 24 hours at the
temperature of 30°C [1,37].
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For conjugation with monoclonal antibody, the general procedure
replaces CTAB as described in the literature [21, 33] on the surface of
GNR with MHDA for activation [34,38], monoclonal antibody (HER2,
purified using desalting columns (Pierce Biotechnology, Rockford, IL)
or a Microcon centrifugal filter device from Millipore), and PEG [21].
Figure 2 presents a schematic of the conjugation protocols investigated
in this work. They differ by the order of the surface modification steps.

Absorbance

Fabrication, PEGylation,
characterization

Before covalent binding with PEG, or conjugation with monoclonal
antibody HER2, the GNR were centrifuged at low speed (1500 × g, 20
min) for separation of unwanted aggregates like platelets and stars.
Figure 1 shows UV-VIS absorption spectra of GNR. The first fraction
comes from resuspension of the pellet after low speed centrifugation
of the GNR-CTAB stock solution (not used in this report). The second
fraction is from the supernatant which was used in all experiments.
Spectra are normalized to match the short wavelength peak of the
GNR-CTAB supernatant data. The GNR-CTAB complex is now ready
for further modification. For pegylation [21,34], the GNR-CTAB
solution was centrifuged at 14000 g for 10 minutes, the supernatant
was removed, and the pellet was resuspended in Milli Q Water (MQW)
to reduce the residual CTAB concentration to 0.01 M. Then, 1.0 ml
of 2 mM K2CO3 was added to 8 ml of aqueous GNR solution and 1.0
ml of 0.1 mM mPEG-Thiol (PEG). The resulting mixture was kept on
a rocking platform at room temperature overnight. Excess PEG was
removed from the solution by two rounds of centrifugation prior to
final resuspension in PBS (pH 7.4).
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Figure 1: UV-VIS absorption spectra of GNR. First fraction is from resuspension
of the pellet after low speed centrifugation of GNR-CTAB stock solution (not
used in this report). The second fraction is from the supernatant which was use
in all experiments. Spectra are normalized to match the short wavelength peak
of the GNR-CTAB supernatant data.
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CL
(step 2)

mAb
(step 3)

GNR-(MHDA/mPEG-SH)
(step 1)

Protocol 2

mAb
(step 2)

spectral properties (UV-VIS spectra into range 400-1100 nm) were
monitored by Beckman 530 or Thermo Scientific Evolution 201
spectrophotometer[39].

Protocol 3
mPEG-SH
(step 3)

GNR-(MHDA+CL)
(step 1)

mAb+CL
(step 2)

mPEG-SH
(step 3)

GNR-MHDA
(step 1)

PEG-GNR-CL-MHDA-mAb

Figure 2: Different protocols for conjugation of GNR with antibody.

of binding with the antibody, while maintaining the plasmon
resonance of the control (GNR-PEG). The spectra are presented in
Figure 3: UV-VIS absorption spectra of GNR-Ab (HER2) conjugates
with different modifications of GNR surface after incubation at 3 hours
in 10% solution of FBS. Control sample is pegylated GNR (PEG). The
other three samples are GNR modified with MHDA and PEG (molar
ratios are 1, 2 and 4 MHDA for 8 PEG: 1M:8P, 2M:8P and 4M:8P,
respectively), activated with cross linkers EDC and sulfo NHS (CL),
then conjugated with Ab HER2.
The heterofunctional linker MHDA was added drop wise to GNR
stock solution under mixing (2.5 µl of 2 mM MHDA for each 1 ml
solution of GNR-CTAB, concentration 500 pM or ratio is 1:10000).
After 60 min of mixing at RT, the GNR were exposed to a solution
mPEG Thiol (2.5 µl of 8 mM PEG for each 1 ml solution of GNRMHDA: ratio is 1:40000) overnight as presented above and reported in
the literature [21,34]. In our experience, this step can be significantly
shortened with no noticeable ill effects. 4-6 hours at RT was found to be
enough for efficient removal of CTAB.
This last step ensures filling the areas not covered by the
heterofunctional MHDA, yielding well-shielded and stable particle
surfaces. Before activation with EDC and sulfo NHS the GNR were
purified by two rounds of centrifugation (12,000 × g, 15 min each),
the supernatant was removed, and the pellet was resuspended in 1 ml
of MQW. 10 µl of a mixture of EDC and sulfo-NHS were added from
stock solution in MES buffer (0.1 M, pH 6.0) with 0.5 M NaCl in 10 mM
and 0.4 mM concentrations, respectively. The resulting solution was
gently agitated for 30 min at RT. The solution was again centrifuged
at 12000 RPM for 10 minutes, the supernatant was removed and mAb
HER2 was added to a final concentration of 100 μg/ml to 1 ml of 500
pM activated GNR. This represents a ratio around 1000 between the
number of Ab molecules and GNR. The mixture was incubated at RT
for 1 hour and then left on a rocking platform overnight (+4oC). The
final step was centrifugation of the solution of conjugates PEG-GNRmAb at 12000 g for 10 minutes. After resuspension, the pegylation step
described above was repeated for 2 h at RT.
Then, the supernatant was removed and the pellet was resuspended
in PBS (pH 7.4) and the conjugates were filtered through a 0.45 µm
Millipore Express Plus membrane. The required concentration,
determined from the molar extinction of our GNR (3.85 × 109
M-1cm-1), was confirmed by optical density measurement and the
J Nanomedic Nanotechnol

			

Protocol 2
The second protocol (Protocol 2, Figure 2) was described before
[33,34] but this work reports have slight modifications. For this,
one ml of synthesized GNR in CTAB was centrifuged twice in a 1.5
mL eppendorf tube at 14000 RPM for 15 minutes and resuspended
in one mL of MQW to a concentration of 500 pM. Then, 10 µL of 5
mM MHDA in ethanol was added to the GNR and the solution was
sonicated for 30 minutes at 50°C to prevent aggregation. The solution
was centrifuged at 12000 RPM for 10 minutes, the supernatant was
removed, and the pellet was resuspended in MQW. 10 µl EDC and
sulfo-NHS was added from stock solution in MES buffer in 10 mM
and 0.4 mM concentrations, respectively. The mixture was sonicated
for 30 minutes at room temperature (RT) to produce activated GNR
(GNR that are capable of binding to the amine side chain of proteins).
HER2 was added, at a final concentration of 100 μg/ml, to 1 ml of 500
pM activated GNR just like in Protocol 1. The mixture was sonicated at
RT for 30min and then left on a rocking platform overnight. Following
the removal of excess HER2, 10 μl of PEG (1 mM) was added to 1 ml
of GNR-HER2 conjugates and the mixture was incubated at room
temperature for 12 h [34]. The solution of GNR-HER2-PEG conjugate
was centrifuged at 12000 g for 10 minutes, the supernatant was
removed and the pellet was resuspended in PBS pH 7.4 to a working
concentration determined spectrophotometrically.

Protocol 3
The third method of activation (Protocol 3) has the modification
steps performed in another order (Figure2). Same one mL of
synthesized GNR in CTAB was resuspended in one mL of MQW.
MHDA was added to the GNR-CTAB solution, and the solution was
sonicated for 30 minutes at 50°C to prevent aggregation. The solution
1.000
0.900
0.800
0.700

Absorbance

Protocol 1

0.600
0.500
0.400
0.300
0.200
0.100
0.000
400

500
PEG

600

700

1M:8P

800
2M:8P

900

1000
4M:8P

1100
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Figure 3: UV-VIS absorption spectra of GNR-Ab (HER2) conjugates with
different modifications of GNR surface after incubation at 3 hours in 10%
solution of FBS. Control sample is pegylated GNR (PEG). The other three
samples are GNR modified with MHDA and PEG (molar ratios are 1, 2 and
4 MHDA for 8 PEG: 1M:8P, 2M:8P and 4M:8P, respectively), activated with
cross linkers EDC and sulfo NHS (CL), then conjugated with Ab HER2.
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The zeta-potential of GNR before and after formation of different
conjugates was measured with a high performance particle sizer
(Malvern Instruments Ltd., Southborough, MA, USA) at 25°C, and ten
20-second runs were performed for each sample [39,40]. Zeta-potential
is a measure of both particle stability and adhesion. More negative or
positive values of zeta-potential are associated with more stable particle
solution, because repulsion between the particles reduces the particle
aggregation [38,40]. (Figure 4) Zeta-Potential (mV) for CTAB coated
GNR stock solution (CTAB), GNR after PEGylation (PEG), GNR
after removed CTAB with MHDA and PEG (MHDA-PEG) and three
different protocols for conjugation and pegylation. GNR with MHDA
and PEG, activated with cross linkers EDC and sulfo NHS (CL) and
conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR with
MHDA, activated with CL, conjugated with Ab and pegylated: GNRMHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated with
Ab CL complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot 3)
(mean ± SEM, n = 10-14 for each conjugate).
A measure of total and bound protein (HER2) was performed
with the Pierce Micro BCA™ Protein Assay Reagent Kit (Pierce).
Concentration of HER2 was measured before, and after addition
of GNR-activated solution: it is dependent upon either the level of
monoclonal antibody, or incubation time. Figure 5 shows Mean
number of HER2 molecules on the surface of GNR after conjugation
through different protocols (synthesis steps for protocol 1, 2 and 3
are the same as in Figure 4). As negative control we used solutions of
antibody without GNR. The determination was performed through
measurement of absorbance at or near 562 nm by Cary 500 UV-VISNIR spectrophotometer [38]. It is important to note that the ratio of
absorbance at 562 nm (proteins relative to BSA) has a coefficient of
variation of only around 10% [39].

Cell culture, viability and cell proliferation
Cell lines BT 474 (Human breast distal carcinoma with HER2
receptor overexpression), MCF 7 (Human breast adenocarcinoma with
HER2 receptor overexpression), MCF 10A (Human breast fibrocystic
disease, no HER2 receptor overexpression), MDCK (normal dog kidney
epithelial cells), and Human lung normal fibroblast were obtained from
American Type Culture Collection (ATCC) and cultured in essential
media with 10% fetal bovine serum.
Cell viability (Figure 6) was determined using the Cytotoxicity
Detection Kit which measures cytotoxicity by detecting lactate
dehydrogenase (LDH) activity released from damaged cells (Roche). It
was described in our previous works [40,41].
Cell survival following GNR conjugates incubation at different
concentrations (50-500 pM) was monitored. BT 474 cells were seeded
J Nanomedic Nanotechnol

			

into a 96-well plate at a density of 2×105 cells/ml in 0.1 ml of media per
well. 3 hours before treatment, media were changed to 0.1 ml of low
serum (0.5%). 0.025 ml of GNR conjugates were added in low serum
media too. After 48 h of incubation with GNR conjugates, the 25 µl
samples of media were collected for measurement of LDH release from
the cells [40,41].
The proliferation of viable cells was determined by examining the
conversion of MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole] to a purple formazan product by metabolically active cells using a kit (Roche). BT 474 cells were used in the
same plate (after removing the 25 µl of media for LDH assay) and the
MTT assay was performed on the pretreated plate with different GNR
cells. Absorbance of the LDH and MTT products was measured on a
plate spectrophotometer (Bio-Tek Instruments, Inc.). Data for LDH
release, MTT assay and LDH/MTT ratios, were measured and calculated from 4–6 replicates. Figure 7 summarizes the results: Metabolically
active cells (MTT assay), LDH release, and ratio between LDH release

70 mV
60
50
40
30
20
10
0
-10 CTAB
-20
-30

PEG

MHDA
-PEG Prot 1 Prot 2 Prot 3

Figure 4: Zeta-Potential (mV) for CTAB coated GNR stock solution (CTAB),
GNR after PEGylation (PEG), GNR after removed CTAB with MHDA and PEG
(MHDA-PEG) and three different protocols for conjugation and pegylation.
GNR with MHDA and PEG, activated with cross linkers EDC and sulfo
NHS (CL) and conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR
with MHDA, activated with CL, conjugated with Ab and pegylated: GNRMHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated with Ab CL
complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot 3) (mean ± SEM,
n=10-14 for each conjugate)

Molecules of Ab per GNR

was centrifuged at 12000 RPM for 10 minutes, the supernatant was
removed and the pellet was resuspended in MQW. At the same time a
complex of mAb and crosslinkers was prepared from mAb and solution
of EDC/sulfo NHS in MES buffer. The compound was agitated at RT
for 30 min. The activated mAb was purified by centrifugation with 3000
kDa membrane (possible use dialysis), and additional washing by salt
column (Pierce). The clean complex was added to the GNR-MHDA
solution and left overnight (4oC). Following the removal of excess mAb
by centrifugation, the GNR-mAb complex was pegylated as shown in
Protocol 2. The resulting solution of GNR-mAb-PEG conjugate was
centrifuged at 12000 g for 10 minutes, the supernatant was removed and
the pellet was resuspended in PBS pH 7.4 to a working concentration
determined spectrophotometrically.

50
40
30
20
10
0

Protocol 1

Protocol 2

Protocol 3

Figure 5: Mean number of HER2 molecules on the surface of GNR after
conjugation through different protocols (synthesis steps for protocol 1, 2 and 3
are the same as in Figure 4).

Functionalized Nanomaterials:
			
Biomedical and Sensing Applications

ISSN:2157-7439 JNMNT an open access journal

Citation: Liopo A, Conjusteau A, Tsyboulski D, Ermolinsky B, Kazansky A, et al. (2012) Biocompatible Gold Nanorod Conjugates for Preclinical
Biomedical Research. J Nanomedic Nanotechnol S2:001. doi:10.4172/2157-7439.S2-001

Page 5 of 10

15

and BT-474 cells following 60 min pre-treatment with pegylated (GNRPEG) or conjugated through protocol 1 (GNR-PEG-HER2) GNR
which were incubated with heparinized mouse blood for four hours.
BT 474 shows silver enhancement for GNR-PEG-HER2 conjugates in
both conditions: before and after incubation of GNR-conjugates with
blood.

%

12
9

Animal studies for optical and optoacoustic imaging

6
3
0

CTL

PEG

BT 474

Prot 1

MCF7

Prot 2

MCF10

Prot 3

MDCK

Figure 6: Fraction of dead cells for the cell lines (BT 474, MCF 7, MCF 10
and MDCK) after incubation with GNR HER2 conjugates for 48 h, 250 pM
(or 1.5 × 1011 GNR/ml). The number of dead cells was counted after staining
with Trypan Blue. Control groups of cells received treatment with PBS or GNR
after PEGylation (PEG). Synthesis steps for protocols 1, 2 and 3 are the same
as in Figure 4 (mean ± SD, n=6 independent measures for each conjugate).
Results indicate significantly higher level of cell death for cells with HER2/neu
expression, BT 474 and MCF7, and no significant changes without HER2/neu
expression: MCF 10 and MDCK.

and MTT following incubation of BT 474 cell with GNR conjugates for
48 h, at concentrations up to 500 pM (or 3 × 1011 GNR/ml). Synthesis
steps for protocols 1, 2 and 3 are the same as in Figure 4 (mean ± SD,
n = 6 independent measures for each conjugate). All protocols show
significant level of cell death, from Prot 1 (highest) to Prot 3 (lowest).
The other technique to assess cell viability is based on trypan blue
(Sigma) dye exclusion [40]. This staining was used for investigation of
cell viability of BT 474, MCF 7, MCF 10 and MDCK cells as well as
for measuring surviving these cells their after incubation with GNRPEG, and conjugates from protocols 1, 2 and 3 (all at 500 pM or 3 ×
10 11 GNR/ml, 48 h, n = 6, M±SD). After this, the cells were incubated
5 min with 0.4% trypan blue, and counted as a percentage of stained
cells to total number of cells. As positive control, we used cells to which
only PBS solution (pH 7.4, at 25°C) was added. Correspondingly,
knowingly toxic CTAB-coated GNR solutions [16] were added in the
same concentrations as GNR conjugates and these samples were used
as negative controls in each experimental condition.
This thorough comparative study had been devised in order to
compare the GNR conjugates fabricated with 3 different protocols, and
assess their relative performance. After confirming suitability, the novel
order of conjugation (Protocol 1) was chosen for all in vitro and in vivo
experiments related to the visualization of receptors and distribution
on GNR conjugates in tumor and liver tissue.
Optical visualization of binding of GNR conjugates with BT 474
cells and fibroblasts was performed through the use of a silver staining
kit (SS, BBI International, UK) according to manufacturer instructions.
Cells with (BT 474) and without (Fibroblasts) overexpression of
HER2 receptors were treated with GNR HER2 conjugates. Incubation
time of GNR conjugates was 1 h. GNR conjugates were pretreated
with heparinized mouse blood (preincubation time is 4 h). Optical
visualization of HER2 receptors was performed after fixation of cells
with a mixture of formaldehyde (2.5%) and glutaraldehyde (1.5%).
Figure 9 shows Silver staining of fibroblast (no HER2/neu expression)
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For investigation of GNR HER2 conjugates distribution we used
(animal models) mice with tumors that overexpressed HER2/neu
receptor. In vivo experiments aimed to evaluate whether GNR HER2
conjugates are accumulated within tumors that overexpress HER2/
neu receptor in the same as in other animal model tissue without
overexpression of this receptor. We used Athymic Nude-Foxn1nu
mice (Harlan), 7-9 weeks old, weighing about 25 g. Animal handling,
GNR conjugates injections, and euthanasia were described in detail
in our publications [15,16] and each mouse-related procedure was in
compliance with our Institutional Animal Care and Use Committee
(IACUC) protocol. This model was made through BT474 cells injection
(2 × 106), subcutaneously in the flank area of nude mice [34]. The
tumors had a diameter of 4-6 mm after three-four weeks.
The mice had 200 µl of GNR conjugates in sterile PBS injected
intravenously (IV) through the tail vein. The injected solution
contained 7.5×1012 GNR/ml or 12.5 nM, which is equivalent to 100-
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Figure 7: Metabolically active cells (MTT assay), LDH release, and ratio
between LDH release and MTT following incubation of BT 474 cell with GNR
conjugates for 48 h, at concentrations up to 500 pM (or 3 × 1011 GNR/ml).
Synthesis steps for protocols 1, 2 and 3 are the same as in figure 4 (mean
± SD, n=6 independent measures for each conjugate). All protocols show
significant level of cell death, from Prot 1 (highest) to Prot 3 (lowest).
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The optimized method of activation of GNR differs by the order
of the modification steps (Protocol 1 on Figure 2). The GNR-CTAB
MQW solution is mixed with MHDA and PEG (in molar ratio 1:4),
and activated though EDC and sulfo-NHS as the complex PEG-GNRMHDA. This complex is capable of conjugation through the carboxy
group of MHDA for binding with an amine function of proteins,
antibody or peptides [4,18]. Optimization of the ratio between MHDA
and PEG was investigated by UV-VIS absorption spectra of GNR-Ab
(HER2) conjugates with different modifications of GNR surface after
incubation at 3 hours in 10% solution of FBS (Figure 3). Conjugated
HER2 on the surface modified with MHDA and PEG was more stable
at 1 and 2 molar parts of MHDA for 8 parts of mPEG thiol. Due to the
two fold increase in number of binding sites with similar stability in
FBS solution, our choice was 1:4 molar ratio. This type of conjugation
has not shown significantly different spectral behavior from pegylated
GNR.
To confirm the chemistry modification of GNR-PEG conjugates we
investigated the Zeta-potential (Figure 4). It was measured for CTAB
coated GNR stock solution (CTAB), GNR after PEGylation (PEG),
GNR after CTAB removal with MHDA and PEG (MHDA-PEG) and
three different protocols for conjugation and pegylation. GNR with
MHDA and PEG, activated with cross linkers EDC and sulfo NHS (CL)
and conjugated with Ab: GNR-MHDA/PEG+CL+A (Prot 1); GNR
with MHDA, activated with CL, conjugated with Ab and pegylated:
GNR-MHDA+CL+Ab+PEG (Prot 2); GNR with MHDA, conjugated
with Ab CL complex and pegylated: GNR+MHDA+CL/Ab+PEG (Prot
3). The zeta-potential (Figure 4) of the GNR-CTAB complex was highly

J Nanomedic Nanotechnol

			

We investigated the influence of concentrations of GNR-PEG
conjugates on the physiological status of cell cultures for different
protocols of GNR conjugations (Figure 6). The cells of four lines (BT
474, MCF 7, MCF 10 and MDCK) were incubated with GNR HER2
conjugates for 48 h, at 250 pM (or 1.5 × 1011 GNR/ml). The number of
dead cells was counted after staining with Trypan Blue [43]. Control
groups of cells received treatment with PBS or GNR after PEGylation
(PEG). Results indicate significantly higher level of cell death for cells
with HER2/neu expression: BT 474 and MCF7. A trend toward increase
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We evaluated the protocol that improves the conjugation process of
mAb to GNR and enhances GNR activity toward targeting antibodies.
A significant part of this evaluation consists in the purification of
GNR-CTAB stock solution. After low speed centrifugation of the stock
solution, the pellet containing mostly platelets, stars, and other nonrod-like particles was discarded and only the supernatant was used
as clean solution of GNR in different modification and conjugations
procedures (Figure 1). In this study we compare three different
protocols of activation and conjugation of GNR with mAb (Figure 2).

Investigation of binding of mAb (HER2) on the surface of activated
GNR is presented in Figure 5 for all the protocols. Comparison of the
different protocols of conjugation with number of HER2 molecules on
the surface of GNR after conjugation shown that Protocol 1 yields the
highest density of HER2 on the surface of GNR.
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positive due to the presence of the positively charged CTAB molecules.
After PEGylation, a negative zeta-potential confirmed chemistry
changes to the GNR surface: the CTAB bi-layer was removed (Figure
4). The GNR HER2 conjugates solution showed a zeta-potential which
is slightly negative, but significantly different from zero. Zeta potential
changes do confirm surface chemistry modifications, and correspond
to previously published data [40,42].
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150 pM after distribution within the mouse’s body. Selected mice were
sacrificed at 48 h after the IV injections of GNR conjugates. Tissues of
liver and tumor extractions were produced as paraffin-imbedded slices
for Silver Staining (SS) and Hematoxylin Eosin (H&E) staining. Tissue
sections (5 µm) were deparaffinized and rehydrated through xylene (3
changes, 5 min each) and graded ethanol solutions from 100 to 50%
(1 min each). After this, samples were rinsed in dH2O and placed in a
water bath for 10 min with tris-buffered saline with Tween 20 (TBST,
Dako, Denmark). Retrieval with Target Retrieval Solution pH 6.1
(TRS, Dako, Denmark) was then performed in a preheated container
at 96-99°C for 30-40 min. The slides of liver sections were stained for
PEG-GNR optical visualization with a SS Kit (BBI International, UK)
according to manufacturer instructions, and HE stained for analysis
of possible pathological consequences in liver after GNR conjugates
administration. The results are shown in Figure 10 Above: Hematoxylin
& Eosin (tumor and liver), and below: silver staining (tumor and liver)
of GNR accumulated in mouse tissues following intravenous injection
of PBS, GNR-PEG or GNR-PEG-HER2 conjugates. Silver staining
shows that GNR peg or Ab conjugates have uniform distribution in
liver tissue and noticeably higher numbers of GNR specific conjugates
in mouse tumors.
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Figure 8: UV-VIS absorption spectra of supernatant solutions of GNR-Ab
(HER2) conjugates after incubation for six hours in heparinized mouse blood.
Synthesis steps for protocols 1, 2 and 3 are the same as in figure 4. Before
and after 1 h incubation all protocols for conjugated and pegylated (PEG
and Prot. 1, Prot. 2 and Prot. 3, respectively) have similar spectra. After 6 h
incubations a higher level of aggregation is observed in samples from Prot 3,
with the best results for Prot.1 (lower aggregation)
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of cell death can be seen for the cell lines without HER2/neu expression:
MCF 10 and MDCK. Following GNR-CTAB administration, the level
of dead cells was 4-5 times higher in comparison with GNR conjugates
and did not show differentiation between groups of cells (data not
presented).
Dose dependence response from BT 474 (overexpressed of HER2
receptors) was investigated by MTT assay, LDH release from the cell
into the media, and ratio between LDH release and MTT following cell
incubation with GNR conjugates for 48 h, at concentrations up to 500
pM (Figure 7). All protocols show significant level of cell death, which
corresponds to ratio of LDH by MTT [16,44]. However consequences
for cell’s, cell death was higher from Protocol 1 conjugates and lowest
from Protocol 3.
Figure 8 shows UV-VIS absorption spectrum of supernatant
solutions of GNR-Ab (HER2) conjugates after incubation for six
hours in heparinized mouse blood. Before and after 1 h incubation.
All protocols for conjugated and pegylated (PEG and Prot. 1, Prot. 2
and Prot. 3, respectively) have similar spectra. After 6 h incubation
period, the pegylated sample shows little change, but a higher level of
aggregation is observed in the conjugated samples, the highest from
Protocol 3, and the lowest (best) results for conjugates from Protocol
1. This type of conjugate is more stable, resulting in an absorption peak
around that of the control pegylated GNR, and can thus maintain the
plasmon resonance in the biological transparency window for longer
times [6,21].
Comparative studies confirmed suitability of the novel order of
conjugation steps, therefore Protocol 1 was used for experiments
related to the characterization of specific targeting of GNR HER2
conjugates with cells in vivo application.
The incubation of GNR-PEG-HER2 conjugates with BT 474 and
fibroblasts has shown to selectively bind to cancer cells after they are
incubated in blood (Figure 9). GNR conjugates were incubated with
heparinized mouse blood for 4 h and then were incubated with both
BT-474 cells as well as fibroblasts for 30 min at 37°C. The cell plates
were rinsed with PBS to remove unattached GNRs, and the plates
were stained using silver enhancement kit. Figure 9 shows a significant
increase in the number of GNR conjugates on the cells surface only for
selective binding to BT-474 cells that overexpress HER2/neu receptor,
but for both experimental conditions: before and after pre incubation
of conjugates with blood. Fibroblasts do not have overexpressed HER2/
neu receptors and silver staining cannot visualize GNR conjugates
on the cell surface. GNR conjugates were added to the media at
a concentration of 500 pM. This concentration is consistent with
reported levels of GNR-PEG in blood or tissue after IV administration
in vivo (12, 22, 23 ml). Results from these experiments are very similar
to data previously published for methods of conjugation similar to
Protocol 2 [34]. However, the novel method is much easier to perform,
less time-consuming and provides a higher yield of conjugated GNR.
In vivo GNR conjugate administration has aimed to evaluate specific
accumulation within tumors that overexpress HER2/neu receptors in
animal models. Figure 10 shows results from an experiment in which
GNR-PEG-HER2 complexes were found to accumulate within tumors
and the liver of animals. 48 hours post tail vein injection, mice were
sacrificed and samples of tumor and liver were stained with H&E and
SS (Figure 10). One group of mice was injected by GNR-PEG-HER2
conjugate, and another with pegylated GNR (GNR-PEG). One mouse
was used as a control and thus was injected with only PBS. HE staining
J Nanomedic Nanotechnol

			

(above) and SS (below) show different cases of GNR accumulated
in mouse tissue following intravenous injection of PBS, GNR-PEG
or GNR-PEG-HER2 conjugates. HE staining did not show a visible
difference between the PBS control and the GNR slices of liver tissue
after IV administration of GNR-PEG conjugates (Figure 10). The
results are consistent with those reported by other groups [32,45]
for similar dosage of GNR (around 10-20 mg/kg body mass), and are
presented solely as confirmation our GNR-PEG complexes are nontoxic. Silver staining shows that GNR PEG or Ab conjugates have
uniform distribution in liver and noticeably higher number of GNR
specific conjugates in mouse tumor.
We present SS data showing the accumulation of PEG-GNR and
GNR-HER2 into liver Kupffer cells in comparable concentration,
as this is not related to selective binding: these cells are specialized
macrophages located in the liver and lining the walls of the sinusoids,
and are responsible for removing non metabolized compounds from
the organism. They are an important part of the reticuloendothelial
system [26].
We used GNR conjugates for IV administration in same dose as
we studied for enhancement of optoacoustic imaging pegylated GNR:

PBS

GNR-PEG

GNR-PEG-mAb

Fibroblasts + GNR Before Incubation with Blood

Fibroblast + GNR After Incubation with Blood

BT 474 + GNR Before Incubation with Blood

BT 474 + GNR After Incubation with Blood
Figure 9: Silver staining of fibroblast (no HER2/neu expression) and BT-474
cells following 60 min pre-treatment with pegylated (GNR-PEG) or conjugated
through protocol 1 (GNR-PEG-HER2) GNR which were incubated with
heparinized mouse blood for four hours. BT 474 shows silver enhancement for
GNR-PEG-HER2 conjugates in both conditions: before and after incubation of
GNR-conjugates with blood.
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PBS
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Biocompatible and nontoxic nanoparticles have been used
for in vivo tumor targeting and detection based on pegylated gold
nanoparticles and surface-enhanced Raman scattering [52]. This team
used two different molecules of PEG, carboxy PEG thiol (3000 Da) for
mAb bonding and PEG thiol (500 DA) for preventing recognition and
degradation by proteolytic enzymes uptake by the RES. Our preliminary
study demonstrated that MHDA with pegylation is preferred for
prevention of aggregation of GNR conjugates in solutions of BSA or
FBS. The method of bifunctional linkage is easier, faster, and more
efficient, in comparison with other methods of removal of CTAB and
along with pegylation can be successfully used for long-time storage
(two-three month) or in vivo application. Additionally, this method
made better masks against recognition of GNR conjugates for in vivo
application, because the “bridge” MHDA-zero size linker (EDC-NHS)mAb is comparable in size (length) as PEG thiol 5000. Furthermore, the
functional activity of Ab is not lost upon conjugating. Accumulation
of GNR conjugates in regions of interest can form a base for contrast
enhancements in many applications such as optical imaging, opto- and
photo- acoustic imaging, optical coherent tomography, thermotherapy
and thermolysis, drug delivery and monitoring, as well as sensing.

Tumor, H&E

Liver, H&E

Tumor, SS

Liver, SS
Figure 10: Above: Hematoxylin & Eosin (tumor and liver), and Below: silver
staining (tumor and liver) of GNR accumulated in mouse tissues following
intravenous injection of PBS, GNR-PEG or GNR-PEG-HER2 conjugates.
Silver staining shows that GNR peg or Ab conjugates have uniform distribution
in liver and noticeably higher number of GNR specific conjugates in mouse
tumor.

around 20 mg/kg/BW [15,16] we believe that specific binding can
significantly improve medical imaging.

Discussion and Summary
Currently, conjugation of biomolecules to gold nanorods can be
divided into four different methodologies: the use of a biofunctional
linker which binds to gold at one end and to biomolecules on the
other end, direct ligand exchange of the CTAB capping molecules
with the biomolecules, functionalized coating of molecules that are
electrostatically adsorbed onto the capping molecules while binding to
biomolecules at their sites of functional groups, and electrostatically
adsorbed onto the capping molecules [18].
The thiol exchange is the most common way to replace the original
capping molecules since the metal–sulfur bond is known to be the
strongest bond among different functional groups: amines, carboxylic
acids, alcohols, and phosphors [18].
Biomolecules such as PEG, [9,21] DNA, [14,46], lipids [47]
and small molecular ligands for cellular biomarkers, [48] are first
functionalized with an alkythiolated linker and then bound to GNR
through Au–S bonds after few hours of reaction [18].
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For some biomolecules, such as antibodies and proteins, thiolation
is complicated by the fact that molecules are too large to reach the
gold surface due to the dense packing of the CTAB double layers.
The use of small bifunctional molecules such as 3-mercaptopropionic
acid (MPA), 11-mercaptoundecanoic acids (MUDA), and
16-Mercaptohexadecanoic acid (MHDA) [34,38,49,50] and cystamine
[51] are useful in these studies. These small bifunctional molecules are
very similar to bifunctional PEG.

In summary, we demonstrated that a combination of pegylation
before conjugating GNR with mAb provided nontoxic GNR-PEGHER2 conjugates with stable plasmon resonance suitable for in vitro
and in vivo applications. We successfully optimized a protocol for
fabrication of GNR conjugates to be suitable as in vivo contrast agent.
We have shown the optimal molar ratio between short functionalized
molecules used as bridges for linkers, and methoxy PEG thiol was
around 1 to 4. During the conjugation step, the optimum ratio between
activated GNR and number of molecules of mAb is around 1000. These
ratios can be used for many biomolecules for conjugation with GNR
for biomedical applications.
Acknowledgements
This work was supported by research grants from the National Institutes of
Health R43ES021629; R44CA110137; R44CA110137-05S1 and SC3GM087201
to AK.

References
1. Liao H, Hafner JH (2005) Gold Nanorod Bioconjugates. Chem Mater 17: 46364641.
2. Perez-Juste J, Pastoria-Santos I, Liz-Marzan LM, Mulvaney P (2005) Gold
nanorods: Synthesis, characterization, and applications. Coord Chem Rev 249:
1870-1901.
3. Alkilany AM, Murphy CJ (2010) Toxicity and cellular uptake of gold
nanoparticles: what we have learned so far? J Nanopart Res 12: 2313-2333.
4. Huang X, El-Sayed IH, El-Sayed MA (2010) Applications of Gold Nanorods for
Cancer Imaging and Photothermal Therapy. Methods Mol Biol 624: 343-357.
5. Tiwari PM, Vig K, Dennis VA, Singh SR (2011) Functionalized Gold
Nanoparticles and Their Biomedical Applications. Nanomaterials 1: 31-63.
6. Oraevsky A (2009) Gold and silver nanoparticles as contrast agents for
optoacoustic imaging, in Photoacoustic imaging and spectroscopy. Taylor and
Francis Group, New York.

Functionalized Nanomaterials:
			
Biomedical and Sensing Applications

ISSN:2157-7439 JNMNT an open access journal

Citation: Liopo A, Conjusteau A, Tsyboulski D, Ermolinsky B, Kazansky A, et al. (2012) Biocompatible Gold Nanorod Conjugates for Preclinical
Biomedical Research. J Nanomedic Nanotechnol S2:001. doi:10.4172/2157-7439.S2-001

Page 9 of 10
7. Khlebstov NG, Dykman LA (2010) Optical properties and biomedical
applications of plasmonic nanoparticles. J Quant Spectrosc Radiat Transf 111:
1-35.

29. Chen S, Ji Y, Lian Q, Wen Y, Shen H, et al. (2010) Gold Nanorods Coated
with Multilayer Polyelectrolyte as Intracellular delivery Vector of Antisense
Oligonucleotides. Nano Biomed Eng 2: 15-23.

8. Jain KK (2010) Advances in the field of nanooncology. BMC Med 8: 83.

30. Zhang X, Pan B, Wang K, Ruan J, Bao C, et al. (2010) Electrochemical
Property and Cell Toxicity of Gold Electrode Modified by Monolayer PAMAM
Encapsulated Gold Nanorods. Nano Biomed Eng 2: 182-188.

9. Dickerson EB, Dreaden EC, Huang X, El-Sayed IH, Chu H, et al. (2008) Gold
nanorod assisted near infrared plasmonic photothermal therapy (PPTT) of
squamous cell carcinoma in mice. Cancer lett 269: 57-66.
10. Urbanska K, Romanowska-Dixon B, Matuszak Z, Oszajca J, Nowak-Sliwinska
P, et al. (2002) Indocyanine green as a prospective sensitizer for photodynamic
therapy of melanomas. Acta Biochim Pol 49: 387-391.
11. Huang X, Jain PK, El-Sayed IH, El-Sayed MA (2007) Gold nanoparticles:
interesting optical properties and recent applications in cancer diagnostics and
therapy. Nanomedicine(Lond) 2: 681-693.
12. Huang X, Jain PK, El-Sayed IH, El-Sayed MA (2006) Determination of the
minimum temperature required for selective photothermal destruction of cancer
cells with the use of immunotargeted gold nanoparticles. Photochem photobiol
82: 412-417.
13. Bonoiu AC, Mahajan SD, Ding H, Roy I, Yong KT, et al. (2009) Nanotechnology
approach for drug addiction therapy: gene silencing using delivery of gold
nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A
106: 5546-5550.
14. Chen CC, Lin YP, Wang CW, Tzeng HC, Wu CH, et al. (2006) DNA-gold
nanorod conjugates for remote control of localized gene expression by near
infrared irradiation. J Am Chem Soc 128: 3709-3715.
15. Su R, Ermilov SA, Liopo AV, Oraevsky AA (2012) Three-dimensional
optoacoustic imaging as a new noninvasive technique to study long-term
biodistribution of optical contrast agents in small animal models. J Biomed Opt
17: 101506.
16. Liopo A, Conjusteau A, Chumakova O, Ermilov S, Su R, et al. (2012) Highly
purified biocompatible gold nanorods for contrasted optoacoustic imaging of
small animal models. Nanoscience and Nanotechnology Letters 4: 1-6.
17. Conjusteau A, Liopo A, Tsyboulski D, Ermilov S, Oraevsky AA, et al. (2011)
Optoacoustic sensor for nanoparticle-linked immunoabsorbent assay
(NanoLISA). Proc SPIE 7899:789910.
18. Huang X, Neretina S, El-Sayed MA (2009) Gold nanorods: from Synthesis and
Properties to Biological and Biomedical Applications. Adv Mater 21: 4880-4910.
19. Liao CK, Huang SW, Wei CW, Li PC (2007) Nanorod-based flow estimation
using a high-frame-rate photoacoustic imaging system. J Biomed Opt 12:
064006.
20. Chamberland DL, Agarwal A, Kotov N, Brian Fowlkes J, Carson PL, et al. (2008)
Photoacoustic tomography of joints aided by an Etanercept-conjugated gold
nanoparticle contrast agent-an ex vivo preliminary rat study. Nanotechnology
19: 095101.
21. Niidome T, Yamagata M, Okamoto Y, Akiyama Y, Takahashi H, et al. (2006)
PEG-modified gold nanorods with a stealth character for in vivo applications. J
Control Release 114: 343-347.
22. Rostro-Kohanloo BC, Bickford LR, Payne CM, Day SE, Anderson LJ, et al.
(2009) The stabilization and targeting of surfactant-synthesized gold nanorods.
Nanotechnology 20: 434005.

31. Xu W, Luo T, Pang B, Li PC, Zhou C, et al. (2012) The radiosensitization of
melanoma cells by gold nanorods irradiated with MV-Xray. Nano Biomed Eng
4: 6-11.
32. Maltzahn G von, Park JH, Agrawal A, Bandaru NK, Das SK, et al. (2009)
Computationally Guided Photothermal Tumor Therapy Using Long-Circulating
Gold Nanorod Antennas. Cancer Res 69: 3892-3900.
33. Rayavarapu RG, Petersen W, Ungureanu C, Post JN, van Leeuwen TG, et
al. (2007) Synthesis and Bioconjugation of Gold Nanoparticles as Potential
Molecular Probes for Light-Based Imaging Techniques. Int J Biomed Imaging
2007.
34. Eghtedari M, Liopo AV, Copland JA, Oraevsky AA, Motamedi M (2009)
Engineering of Hetero-Functional Gold Nanorods for the in vivo Molecular
Targeting of Breast Cancer Cells. Nano Lett 9: 287-291.
35. Green HN, Martyshkin DV, Rodenberg CM, Rosenthal EL, Mirov SB (2011)
Gold nanorods bioconjugates for active tumor targeting and photothermal
therapy. Journal of Nanotechnology 2011: 1-7.
36. Nikoobakht B, El-Sayed MA (2003) Preparation and Growth Mechanism of
Gold Nanorods (NRs) Using Seed-Mediated Growth Method. Chem Mater 15:
1957-1962.
37. Sau TK, Murphy CJ (2004) Seeded High Yield Synthesis of Short Au Nanorods
in Aqueous Solution. Langmuir 20: 6414-6420.
38. Liopo AV, Conjusteau A, Konopleva M, Andreeff M, Oraevsky AA (2012) Laser
nanothermolysis of human leukemia cells using functionalized plasmonic
nanoparticles. Nano Biomed Eng 4: 66-75.
39. Liopo A, Conjusteau A, Oraevsky A (2012) PEG-coated gold nanorod
monoclonal antobody conjugates in preclinical research with optoacoustic
tomography, photothermal therapy, and sensing. Proc SPIE.
40. Chumakova OV, Liopo AV, Andreev VG, Cicenaite I, Evers BM, et al. (2008)
Composition of PLGA and PEI/DNA nanoparticles improves ultrasoundmediated gene delivery in solid tumors in vivo. Cancer lett 261: 215-225.
41. Liopo AV, Stewart MP, Hudson J, Tour JM, Pappas TC (2006) Biocompatibility
of native and functionalized single-walled carbon nanotubes for neuronal
interface J Nanosci Nanotechnol 6: 1365-1374.
42. Alkilany AM, Nagaria PK, Wyatt MD, Murphy CJ (2010) Cation exchange on
the surface of gold nanorods with a polymerizable surfactant: polymerization,
stability and toxicity evaluation. Langmuir 26: 9328-9333.
43. Chumakova OV, Liopo AV, Evers BM, Esenaliev RO (2006) Effect of
5-fluorouracil, Optison and ultrasound on MCF-7 cell viability. Ultrasound Med
Biol 32: 751-758.
44. MacDonald HR (2000) CD1d-glycolipid tetramers: A new tool to monitor natural
killer T cells in health and disease. J Exp Med 192: F15-20.

23. Niidome T, Ohga A, Akiyama Y, Watanabe K, Niidome Y, et al. (2010) Controlled
release of PEG chain from gold nanorods: targeted delivery to tumor. Bioorg
Med Chem 18: 4453-4458.

45. Motamedi S, Shilagard T, Edward K, Koong L, Qui S, et al. (2011) Gold
nanorods for intravital vascular imaging of preneoplastic oral mucosa. Biomed
Opt Express 2: 1194-1203.

24. Rayavarapu RG, Petersen W, Hartsuiker L, Chin P, Janssen H, et al. (2010)
In vitro toxicity studies of polymer-coated gold nanorods. Nanotechnology 21:
145101.

46. Dujardin E, Hsin LB, Wang CRC, Mann S (2001) DNA-driven self-assembly of
gold nanorods. Chem Commun 1264-1265.

25. Weisbecker CS, Merritt MV, Whitesides GM (1996) Molecular Self- Assembly
of Aliphatic Thiols on Gold Colloids. Langmuir 12: 3763-3772.

47. Nakashima H, Furukawa K, Kashimura Y, Torimitsu K (2008) Self-Assembly
of Gold Nanorods Induced by Intermolecular Interactions of Surface-Anchored
Lipids. Langmuir 24: 5654-5658.

26. Roberts MJ, Bentley MD, Harris JM (2002) Chemistry for peptide and protein
PEGylation. Adv Drug Deliv Rev 54: 459-476.
27. Liao H, Nehl CL, Hafner JH (2006) Biomedical applications of plasmon resonant
metal nanoparticles. Nanomedicine (Lond) 1: 201-208.
28. Huang HC, Rege K, Heys JJ (2010) Spatiotemporal temprature distribution and
cancer cell death in response to extracellular hyperthermia induced by gold
nanorods. ACS Nano 4: 2892-2900.

J Nanomedic Nanotechnol

			

48. Huff TB, Hansen MN, Zhao Y, Cheng JX, Wei A (2007) Controlling the cellular
uptake of gold nanorods. Langmuir 23: 1596-1599.
49. Yu C, Varghese L, Irudayaraj J (2007) Surface modification of
cetyltrimethylammonium bromide-capped gold nanorods to make molecular
probes. Langmuir 23: 9114-9119.
50. Dai Q, Coutts J, Zou J, Huo Q (2008) Surface modification of gold nanorods

Functionalized Nanomaterials:
			
Biomedical and Sensing Applications

ISSN:2157-7439 JNMNT an open access journal

Citation: Liopo A, Conjusteau A, Tsyboulski D, Ermolinsky B, Kazansky A, et al. (2012) Biocompatible Gold Nanorod Conjugates for Preclinical
Biomedical Research. J Nanomedic Nanotechnol S2:001. doi:10.4172/2157-7439.S2-001

Page 10 of 10
through a place exchange reaction inside an ionic exchange resin. Chem
Commun (Camb) 2858-2860.

photoacoustic molecular imaging with simultaneous multiple selective targeting
using antibody-conjugated gold nanorods. Opt Express 16: 18605-18615.

51. Li PC, Wang CR, Shieh DB, Wei CW, Liao CK, et al. (2008) In vivo

52. Qian X, Zhou X, Nie S (2008) Surface-enhanced Raman nanoparticle beacons
based on bioconjugated gold nanocrystals and long range plasmonic coupling.
J Am Chem Soc 130: 14934-14935.

Submit your next manuscript and get advantages of OMICS
Group submissions
Unique features:
•
•
•

User friendly/feasible website-translation of your paper to 50 world’s leading languages
Audio Version of published paper
Digital articles to share and explore

Special features:

This article was originally published in a special issue, Functionalized
nanomaterials: Biomedical and Sensing Applications handled by Editor(s).
Dr. Sadeghi SM, University of Alabama in Huntsville, USA

J Nanomedic Nanotechnol

			

•
•
•
•
•
•
•
•

200 Open Access Journals
15,000 editorial team
21 days rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/biochem

Functionalized Nanomaterials:
			
Biomedical and Sensing Applications

ISSN:2157-7439 JNMNT an open access journal

